Latitude Pharmaceuticals

Executive Summary

Latitude Pharmaceuticals, founded in 2003 and based in San Diego, is a private contract research and manufacturing organization (CRO/CMO) specializing in solving complex drug formulation challenges. The company focuses on insoluble, unstable, or poorly bioavailable compounds, leveraging proprietary drug delivery platforms and GLP/GMP services. Serving global biotech and pharmaceutical clients in both human and veterinary medicine, Latitude addresses a critical need in drug development, where approximately 40% of new chemical entities suffer from poor bioavailability. Its niche expertise positions it as a valuable partner for companies seeking to advance challenging drug candidates through preclinical and clinical stages. Despite being a service-based organization with no disclosed funding or valuation, Latitude's established track record and growing demand for formulation solutions suggest steady revenue growth. However, the lack of publicly available financials and limited commercial product output keeps its profile low. The company's success is tied to client project wins and repeat business, which are inherently less predictable than product-driven pipelines.

Upcoming Catalysts (preview)

• Q3 2026Launch of a next-generation drug delivery platform targeting oral bioavailability of peptides70% success
• TBDMajor partnership with a top-20 pharmaceutical company for formulation development of a late-stage asset50% success
• Q1 2027Expansion of GMP manufacturing capacity to support commercial-scale production for veterinary clients60% success